Toxicarioside O (TCO), a natural product derived from Antiaris toxicaria, has been identified to be a promising anticancer agent. In this study, we aimed to investigate the effect of TCO on the proliferation and epithelial-mesenchymal transition (EMT) of lung cancer cells and its molecular mechanisms. Here, we indicated that TCO inhibits the proliferation of lung cancer cells both in vitro and in vivo. Our results demonstrated that TCO induces apoptosis in lung cancer cells. Moreover, we found that TCO suppresses EMT program and inhibits cell migration in vitro. Mechanistically, TCO decreases the expression of trophoblast cell surface antigen 2 (Trop2), resulting in inhibition of the PI3K/Akt pathway and EMT program. Overexpression of Trop2 rescues TCO-induced inhibition of cell proliferation and EMT. Our findings demonstrate that TCO markedly inhibits cell proliferation and EMT in lung cancer cells and provides guidance for its drug development.

**Keywords:** lung cancer cells, toxicarioside O, cell proliferation, epithelial-mesenchymal transition, trophoblast cell surface antigen 2

**INTRODUCTION**

Toxicarioside O (TCO) is one of the cardenolides isolated from the seeds of Antiaris toxicaria (1). Traditionally, cardenolides have been used for the treatment of congestive heart failure and arrhythmia (2, 3). Recently, accumulating evidence has indicated that cardenolides have significant anticancer effects in various types of human cancer cell (4, 5). Consistent with these findings, TCO exhibits significant cytotoxicity against hepatocellular carcinoma cell line SMMC-7721 and human...
leukemic cell line K562 (1). We have previously demonstrated that TCO inhibits cell proliferation and induces protective autophagy in colorectal cancer cells (6). However, the effect of TCO on the proliferation and epithelial-mesenchymal transition (EMT) of lung cancer cells and its molecular mechanisms remain largely unknown.

Trophoblast cell surface antigen 2 (Trop2), also known as human tumor-associated calcium signal transducer 2 (Tacstd2), is a surface glycoprotein originally identified in human placental trophoblasts (7, 8), which is seldom expressed in normal tissues but highly expressed in various cancer cells, such as pancreatic cancer (9), gastric cancer (10), lung cancer, and colorectal cancer (11–13). Trop2 overexpression correlates with increased tumor recurrence, invasiveness, and poor clinical outcome, which is considered as a candidate tumor prognostic marker and a promising and important therapeutic target (12, 14–16).

Trop2 is considered to have an important function in the promotion of epithelial-to-mesenchymal transition (EMT). EMT is referred to changes in cell phenotypes from epithelial to mesenchymal states which mediate cancer progression, metastasis, and drug resistance (17–19). It has been reported that Trop2 induces EMT by binding to β-catenin and promotes cancer progression in gastric cancer (20). Trop2 also activates the JAK2/STAT3 pathway to promote EMT formation and metastasis in glioblastoma cells (21). Trop2 overexpression promotes metastasis by inducing EMT in human breast cancer and lung cancer (22, 23). The ability of Trop2 in regulation of EMT indicated that Targeting to Trop2 should be an alternative method to regulate EMT in cancer treatment. In this study, our results indicated that TCO inhibits cell proliferation and EMT in lung cancer cells by downregulation of Trop2, demonstrating the therapeutic potential of TCO for lung cancer treatment.

MATERIALS AND METHODS

Cell Culture, Agents, and Antibodies

Human non-small cell lung carcinoma (NSCLC) cell line A549 and H1299 cells were purchased from the American Type Culture Collection. All cell lines (about in passage number 6–8, mycoplasma-free) were cultured according to the guidelines and maintained in RPMI-1640 supplemented with 10% FBS (Gibco) at 37°C in an atmosphere containing 5% CO2. TCO was gifted kindly from Prof. Hao-Fu Dai. The purity of TCO was determined by measuring the absorbance at 450 nm. TCO was dissolved in dimethyl sulfoxide (100% DMSO) and stored at ≥95% by chromatographic analysis. TCO was proved to be ≥95% by chromatographic analysis. TCO was dissolved in dimethyl sulfoxide (100% DMSO) and stored at −20°C for experimental use in this study. A BrdU Cell Proliferation Assay Kit was obtained from Abcam. An Annexin-V-FITC/PI Apoptosis Detection Kit was obtained from KeyGEN Biotech. The following antibodies were used in this study: Trop2 (ab214488) was purchased from Abcam; Cleaved caspase-3 (9661T), Cleaved PARP (5625T), Phospho-Akt (4060S), Akt (8596), Phospho-Pi3K p85 (17366), Pi3Kp85 (4292), E-cadherin (3195S), N-cadherin (13116S), Vimentin (12826), and Snail (3879) were obtained from Cell Signaling Technology.

Cell Viability Assay

The cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma, M2128) assay. Briefly, cells (3 × 103 cells/well) were seeded in 96-well plates for 24 h and after treatment, 10 μl of MTT was added to each well and incubated for 4 h. Subsequently, medium was removed and 200 μl of 100% DMSO was added to dissolve the crystal formazan dye. The absorbance value was then determined at 570 nm.

BrdU Assay

BrdU signaling was determined by a BrdU Cell Proliferation Assay Kit (Abcam, ab126556). Briefly, cells (3 × 103 cells/well) were seeded in 96-well plates and after treatment, BrdU was added and incubated for 12 h. BrdU signaling was then determined by measuring the absorbance at 450 nm.

Colony Formation Assay

Cells (300 cells/well) were seeded in 24-well plates and treated with the indicated concentration of TCO. After 2 weeks, the colonies were stained with Giemsa for 15 min and washed three times by PBS. The visible colonies were photographed by a Molecular Imager Gel Do XR+ System (Bio-Rad) and counted using Image J software (NIH).

Flow Cytometry

The indicated cells treated with the tested compounds (0, 1, and 2 μM) for 24 h were harvested and washed with PBS, then resuspended and incubated with PI/Annexin-V solution (KeyGEN Biotech). Apoptosis was analyzed with FACSCalibur flow cytometer (sysmex, CyFlow@ Cube 6, Germany), and data were analyzed by FlowJo7.6.1 software.

Western Blotting

Cells were harvested and lysed with RIPA buffer (Thermo Fisher Scientific, 89900) and the concentrations of protein were quantified by BCA protein assay kit (Thermo, 23227). Proteins (20 to 60 μg) were separated by SDS-PAGE for 80 min and transferred to PVDF membranes for 90 min (IPVH00010, Merck Millipore, Billerica, MA, USA). Membranes were blocked with a buffer containing Tris (10 mM, pH 7.4), NaCl (150 mM), Tween 20 (0.1%), and bovine serum albumin (5%) for 2 h. After blocking, the membranes were incubated with primary antibodies: Trop2 (1:2,000), Cleaved caspase-3 (1:1,000), Cleaved PARP (1:1,000), Phospho-Akt (1:2,000), Akt (1:1,000), Phospho-Pi3K p85 (1:1,000), Pi3Kp85 (1:1,000), E-cadherin (1:1,000), N-cadherin (1:1,000), Vimentin (1:1,000), and Snail (1:1,000). Subsequently, the blots were probed with secondary antibodies at room temperature for 2 h. Target proteins were detected by enhanced chemiluminescence reagents (WBKLS0100; Merck Millipore).

Immunofluorescence

Cells were fixed with 4% paraformaldehyde for 30 min, washed three times with PBS, and then incubated with 0.1% Triton X-100.
Toxicarioside O Regulate Trop2

Zheng et al.

RESULTS

Toxicarioside O Inhibits Cell Proliferation and Induces Apoptosis in Lung Cancer Cells

To investigate the effect of TCO on lung cancer cells, we examined the cell viability by MTT assay. As shown in Figure 1A, TCO treatment decreased the cell viability in a dose-dependent manner in both cell lines. Consistently, BrdU assay showed that cell growth was reduced under TCO treatment (Figure 1B). Moreover, TCO markedly inhibited cell proliferation in lung cancer cells, as evidenced by reduced colony formations (Figure 1C). Taken together, our findings indicated that TCO inhibits cell proliferation in lung cancer cells.

To determine whether TCO induces apoptosis in lung cancer cells, we examined apoptosis by flow cytometry following Annexin V-FITC and propidium iodide (PI) staining. As shown in Figure 1D, TCO treatment for 24 h significantly increased the ratio of apoptotic cells in both A549 and H1299 cells. Consistent with this observation, we observed increased the levels of cleaved caspase-3 and cleaved PARP in TCO-treated cells (Figure 1D). Taken together, our findings demonstrated that TCO induces apoptosis in lung cancer cells.

Toxicarioside O Suppresses EMT and Inhibits Cell Migration in Lung Cancer Cells

To determine whether epithelial-mesenchymal transition (EMT) is involved in TCO-mediated antitumor effect in lung cancer cells, we examined the expressions of E-cadherin, N-cadherin, Vimentin, and Snail1 in TCO-treated cells. As shown in Figure 2A, TCO treatment significantly increased E-cadherin and decreased N-cadherin, Vimentin, and Snail1 expression in both cells by immunoblot analysis. Consistently, immunofluorescence staining assays showed that TCO increased E-cadherin and decreased N-cadherin expression in both cells (Figure 2B). Taken together, these results indicated that TCO suppresses EMT in lung cancer cells.

To validate whether TCO inhibits cell migration in lung cancer cells, we examined the cell migration viability by wound healing assay. As shown in Figure 3A, TCO treatment significantly suppressed cell migration in both cells. Collectively, transwell migration assay showed that TCO treatment significantly inhibited cell migration in lung cancer cells (Figure 3B). Collectively, these results indicated that TCO inhibits cell migration in lung cancer cells.

Toxicarioside O Inhibits the PI3K/Akt Pathway in Lung Cancer Cells

To determine whether the PI3K/Akt pathway is involved in TCO-mediated antitumor effect in lung cancer cells, we

Statistical Analysis

Statistical analysis was performed with GraphPad Prism 6.0 (GraphPad Software). Statistical differences between the two groups were performed by the Student’s t-test. Data were shown as means ± s.d. and statistical significance was designated as follows: *P < 0.05, **P < 0.01, and ***P < 0.001.
examined the phosphorylation levels of Akt (Ser473) and PI3Kp85 (Y607). As shown in Figure 4A, TCO markedly decreased the phosphorylation levels of Akt and PI3Kp85, suggesting that TCO inhibits the PI3K/Akt pathway in lung cancer cells. Moreover, we expressed a constitutively active form of Akt (CA-Akt) to restore TCO-induced inhibition of the PI3K/Akt pathway (Figure 4B). As shown in Figures 4C, D, Akt activation significantly restored cell viability in TCO-treated cells. Consistently, similar results were observed by colony formation assay (Figure 4E). Taken together, these results indicated that TCO suppresses cell proliferation in lung cancer cells by inhibition of the PI3K/Akt pathway.

**Toxicarioside O Decreases Trop2 Expression in Lung Cancer Cells**

To determine whether trophoblast cell surface antigen 2 (Trop2) is involved in TCO-mediated antitumor effect in lung cancer cells, we firstly examined the expression of Trop2 in TCO-treated cells. As shown in Figure 5A, TCO treatment markedly decreased the expression of Trop2 in lung cancer cells. Overexpression of Trop2 reverted the phosphorylation levels of Akt (Ser473) in TCO-treated cells (Figures 5B, C). We observed that Trop2 overexpression restored cell viability in TCO-treated cells by MTT assay (Figure 5D). Moreover, Trop2 overexpression obviously rescued TCO-induced apoptosis (Figures 5E, F). Collectively, these results demonstrated that TCO inhibits cell proliferation and promotes apoptosis in lung cancer cells by downregulation of Trop2.

To determine whether Trop2 is involved in TCO-mediated EMT suppression in lung cancer cells, we overexpressed Trop2 and examined the expressions of E-cadherin and N-cadherin. As shown in Figure 6A, overexpression of Trop2 markedly inhibits E-cadherin expression but promotes N-cadherin expression in TCO-treated cells. Consistently, similar results were observed by
immunofluorescence staining assay (Figure 6B). Moreover, we found that Trop2 overexpression markedly rescued TCO-mediated migration inhibition (Figures 6C, D). Taken together, these results indicated that TCO suppressed EMT in lung cancer cells by downregulation of Trop2.

Toxicarioside O Inhibits Tumor Growth In Vivo
To evaluate the effect of TCO on lung cancer growth in vivo, A549 and dA549 cells transfected with pcDNA3.1-Trop2 (or H1299 and H1299 cells transfected with pcDNA3.1-Trop2)

---

**FIGURE 2** | Toxicarioside O suppresses EMT in lung cancer cells. (A) Immunoblot analysis of E-cadherin, N-cadherin, Vimentin, and Snail1 in A549 and H1299 cells. (B) Immunofluorescent staining for E-cadherin and N-cadherin in A549 and H1299 cells. Relative fluorescence intensity was analyzed by ImageJ. Scale bars, 50 mm. The experiment was repeated three times. *P < 0.05, **P < 0.01, ***P < 0.001.
were implanted subcutaneously in BALB/c nude mice and treated with TCO or DMSO. The images of tumor masses (five in each group) were observed as shown in Figure 7A. Compared to the Ctrl group, the tumors in TCO and TCO+Trop2 groups grew significantly slower, and the TCO group grew the slowest, respectively (Figure 7B). These data indicated that TCO significantly inhibited the growth of lung cancer \textit{in vivo}, and Trop2 overexpression markedly rescued TCO-mediated tumor growth inhibition.

**DISCUSSION**

In recent years, cardenolides, which is traditionally used in the management of congestive heart failure and arrhythmia, have got much attention due to their antitumor effect (2, 3). Toxicarioside O (TCO) is one of the cardenolides isolated from the seeds of \textit{Antiaris toxicaria} that exhibits potential anticancer activities. TCO significantly inhibits cell proliferation in SMMC-7721 and K562 (1). We have previously demonstrated that TCO promotes apoptotic cell death and induces protective autophagy in colorectal cancer cells (6). In this study, we demonstrated that TCO markedly inhibits cell proliferation, migration, and epithelial-to-mesenchymal transition (EMT) in lung cancer cells. Moreover, we revealed that TCO inhibits cell proliferation and migration by downregulation of trophoblast cell surface antigen 2 (Trop2), indicating that Trop2 plays a critical role in TCO-mediated antitumor effect in lung cancer cells.

Trop2, also known as human tumor-associated calcium signal transducer 2 (Tacstd2), is a surface glycoprotein upregulated in various cancer cells (7, 8). Trop2 overexpression is associated with poor survival in human solid tumors, and it has been...
considered as a potential target for anticancer therapy (12, 14). Blockade of Trop2 by anti-Trop2 antibodies exhibits potential anticancer activities (24, 25), and suppression of Trop2 by a natural product of Curcumin significantly inhibits cell proliferation and motility in bladder cancer cells (26). Additionally, RNAi-mediated Trop2 loss markedly triggers antitumor response in some cancer cell lines (27, 28). Consistent with these findings, here we demonstrated that downregulation of Trop2 by a natural product of TCO significantly inhibits cell proliferation and EMT in lung cancer cells. Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene and its overexpression is found in several types of cancer. Although several transcription factors have been identified to regulate its expression, the mechanisms of Trop2 regulation are still unclear (14, 29, 30). In this study, we demonstrated that TCO downregulates Trop2 expression in protein level in lung cancer cells, but how to modulate Trop2 expression by TCO needs further study.

![Figure 4](image.png)

**FIGURE 4** | Toxicarioside O inhibits the PI3K/Akt pathway in lung cancer cells. (A) Immunoblot analysis of phosphorylation of Akt (Ser473) and PI3K p85 (Y607) in A549 and H1299 cells. Total Akt and PI3K p85 expression served as an internal control. (B) Cells were transfected with an empty vector or constitutively active CA-Akt for 48 h, and then cells were treated with 2 μM of TCO for another 24 h. The p-Akt was determined by immunoblotting. (C, D) Cell viability was determined by MTT assay in A549 and H1299 cells stably expressing CA-Akt. (E) Cell proliferation was determined by colony formation assay in A549 and H1299 cells stably expressing CA-Akt. The experiment was repeated three times. *P < 0.05, **P < 0.01, ***P < 0.001.
including PI3K/Akt pathway. Trop2 overexpression activates the PI3K/Akt pathway, and promotes cell proliferation and invasion (31, 32). In contrast, blockage of Trop2 by antibodies or downregulation of Trop2 by natural products suppresses cell proliferation in cancer cells through inhibition of PI3K/Akt pathway (12, 33). In this study, our results demonstrated that TCO suppresses cell proliferation in lung cancer cells by inhibition of the PI3K/Akt pathway. Furthermore, we revealed that TCO inhibits the PI3K/Akt pathway by downregulation of Trop2.

EMT is referred to changes in cell phenotypes from epithelial to mesenchymal states which mediates cancer cell mobility, invasion, and drug resistance (17–19). Accumulating evidence suggested that Trop2 induces EMT and promotes cancer progression in several types of cancer. Trop2 has been regarded as a potential biomarker for the promotion of EMT in human breast cancer (22). Trop2 overexpression promotes migration and metastasis of gallbladder cancer cells by inducing EMT and knockdown of Trop2 suppresses EMT and inhibits migration in endometrial cancer (31, 33). In this study, our
results indicated that TCO suppresses EMT and inhibits cell migration by downregulation of Trop2 in lung cancer cells, but the molecular mechanism of EMT regulation will be further explored in the future.

In summary, we demonstrated that TCO suppresses cell proliferation and EMT in lung cancer cells. We further revealed that TCO decreases Trop2 expression, leading to inhibition of the PI3K/Akt pathway and EMT suppression. Overexpression of Trop2...
rescues TCO-mediated inhibition of cell proliferation and EMT in lung cancer cells. Our findings provide novel insights into the molecular basis for the anti-cancer effect of TCO, and demonstrate that TCO is a potential anticancer agent against lung cancer.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary materials. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The animal study was reviewed and approved by the ethics committee of Hainan Medical University (grant number: HY-2018-1004).

REFERENCES

1. Zuo W-J, Dong W-H, Jing C, Zhao Y-X, Chen H-Q, Mei W-L, et al. Two new strophanthidol cardenolides from the seeds of Antiaris toxicaria. Phytochem Lett (2013) 6(1):1–4. doi: 10.1016/j.phytol.2012.10.001
2. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation (2006) 113(21):2556–64. doi: 10.1161/CIRCULATIONAHA.105.560110
3. Shi LS, Liao YR, Su MJ, Lee AS, Kuo PC, Damu AG, et al. Cardiac glycosides from Antiaris toxicaria with potent cardiotonic activity. J Nat Prod (2010) 73(7):1214–22. doi: 10.1021/np9005212
4. Stenkvist B. Cardenolides and cancer. Anticancer Drugs (2001) 12(7):635–8. doi: 10.1097/00001813-200108000-00012
5. Wen S, Chen Y, Lu Y, Wang Y, Ding L, Jiang M. Cardenolides from the Apocynaceae family and their anticancer activity. Fitoterapia (2016) 112:74–84. doi: 10.1016/j.fitote.2016.04.023

FIGURE 7 | Toxicarioside O inhibits tumor growth in vivo. A549 cells, A549 cells transfected with pcDNA3.1-Trop2, H1299 cells and H1299 cells transfected with pcDNA3.1-Trop2 (2 × 10^6 cells/mouse) were implanted subcutaneously in BALB/c nude mice. When the tumor volume was palpable (~50 mm³ at day 6), mice were treated with indicated formulations every 2 days for five total treatments. (A) Images of tumor masses at day 28 in each mouse. (B) Tumor volumes at different time points. The experiment was repeated three times. **P < 0.01.

AUTHOR CONTRIBUTIONS

W-PZ, F-YH, and S-ZD designed, carried out the experiments, analyzed the data, and prepared the draft of manuscript. J-YW, Y-YL, and YS conducted the experiments and provided materials for biological assays. G-HT and Y-HH conceived the idea, supervised all research, and revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was funded by the Natural Science Foundation of Hainan Province (819MS062) and the National Natural Science Foundation of China (81860429, 81660004, 81760634, 81860650, and 81673346).
6. Huang YH, Sun Y, Huang FY, Li YN, Wang CC, Mei WL, et al. Toxicarioside O induces protective autophagy in a sirtuin-1-dependent manner in colorectal cancer cells. Oncotarget (2017) 8(32):52783–91. doi: 10.18632/oncotarget.17189

7. Ripani E, Sacchetti A, Corda D, Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer (1998) 76(5):671–6. doi: 10.1002/(sici)1097-0215(19980529)76:5<671::aid-ijc10>3.0.co;2-7

8. Lipinski M, Parks DR, Rouse RV, Herzenberg LA. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci U S A (1981) 78(8):5147–50. doi: 10.1073/pnas.78.8.5147

9. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer (2008) 99(8):1290–5. doi: 10.1038/sj.bc.6604677

10. Zhao W, Zhu H, Zhang S, Yong H, Wang W, Zhou Y, et al. Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget (2016) 7(5):6136–45. doi: 10.18632/oncotarget.6733

11. Inamura K, Yokouchi Y, Kobayashi M, Ninomiya H, Sakakibara R, Subat S, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget (2017) 8(17):28725–35. doi: 10.18632/oncotarget.15647

12. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res (2006) 12(10):3057–63. doi: 10.1158/1078-0432.CCR-05-1961

13. Zhao P, Zhang Z. TNF-alpha promotes colon cancer cell migration and invasion by upregulating TROP-2. Oncol Lett (2018) 15(3):3820–7. doi: 10.3892/ol.2018.7735

14. Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, La Sorda R, et al. The Trop-2 signalling network in cancer growth. Oncogene (2013) 32(12):1594–600. doi: 10.1038/onc.2012.151

15. Zaman S, Javid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors future prospects. Onco Targets Ther (2019) 12:1781–90. doi: 10.2147/OTT.S162447

16. Sin STK, Li Y, Liu M, Ma S, Guan XY. TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling. Gynecol Oncol (2019) 152(1):185–93. doi: 10.1016/j.ygyno.2018.10.039

17. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 119(6):1420–8. doi: 10.1172/JCI39104

18. Scheel C, Weinberg RA. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer (2011) 129(10):2310–4. doi: 10.1002/ijc.26311

19. Thiry JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell (2009) 139(5):871–90. doi: 10.1016/j.cell.2009.11.007

20. Zhao W, Jia L, Kuai X, Tang Q, Huang X, Yang T, et al. The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated beta-catenin in gastric cancer. Cancer Med (2019) 8 (3):1135–47. doi: 10.1002/cam4.1934

21. Hou J, Lv A, Deng Q, Zhang G, Hu X, Cui H. TROP2 promotes the proliferation and metastasis of gobletoma cells by activating the JAK2/STAT3 signaling pathway. Oncol Rep (2019) 41(2):753–64. doi: 10.3892/or.2018.6859

22. Zhao W, Kuai X, Zhou X, Jia L, Wang J, Yang X, et al. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer. Oncol Rep (2018) 40(2):759–66. doi: 10.3892/or.2018.6496

23. Li Z, Jiang X, Zhang W. TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells. Biochem Biophys Res Commun (2016) 470(1):197–204. doi: 10.1016/j.bbrc.2016.01.032

24. Redlich N, Robinson AM, Nickel KP, Stein AP, Wheeler DL, Adkins DR, et al. Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma. Cell Death Dis (2018) 9(1):5. doi: 10.1038/s41419-017-0029-0

25. Nishimura T, Mitsunaga M, Sawada R, Saruta M, Kobayashi H, Matsumoto N, et al. Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody. Cancer Med (2019) 8(18):7781–92. doi: 10.1002/cam4.2658

26. Zhang L, Yang G, Zhang R, Dong L, Chen H, Bo J, et al. Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells. Int J Oncol (2018) 53(2):515–26. doi: 10.3892/ijo.2018.4423

27. Gao XY, Zhu YH, Zhang LX, Lu HY, Jiang AG. siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells. Exp Ther Med (2015) 10(2):429–34. doi: 10.3892/etm.2015.2530

28. Zhang J, Ma H, Yang L, Yang H, He Z. Silencing of the TROP2 gene suppresses proliferation and invasion of hepatocellular carcinoma HepG2 cells. J Int Med Res (2019) 47(3):1319–29. doi: 10.1177/0300060518822913. 30060518822913.

29. Shvartsur A, Bonavida B. Trop-2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer (2015) 6(3-4):84–105. doi: 10.18632/genesandcancer.40

30. McDougall AR, Toklos M, Hooper SB, Cole TJ, Wallace MJ, Trop-2 from development to disease. Dev Dyn (2015) 244(2):99–109. doi: 10.1002/dvdy.24242

31. Li X, Teng S, Zhang Y, Zhang W, Zhang X, Xu K, et al. TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT. Oncotarget (2017) 8 (29):47032–63. doi: 10.18632/oncotarget.16789

32. Tang G, Tang Q, Jia L, Chen Y, Lin L, Kuai X, et al. TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway. Int J Mol Med (2019) 44(6):2161–70. doi: 10.3892/ijmm.2019.4378

33. Sun X, Xing G, Zhang C, Lu K, Wang Y, He X. Knockdown of Trop2 inhibits proliferation and migration and induces apoptosis of endometrial cancer cells via AKT/beta-catenin pathway. Cell Biochem Funct (2020) 38(2):141–8. doi: 10.1002/cbf.3450

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zheng, Huang, Dai, Wang, Lin, Sun, Tan and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.